Lactobacillus plantarum TY-P23 and application thereof

Abstract

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus plantarum TY-P23 and application thereof, and the preservation number of the lactobacillus plantarum TY-P23 is CGMCC No: 30876. The lactobacillus plantarum TY-P23 has the functions of remarkably improving the immunity of the body and improving the intestinal injury of the body.

Description

Technical Field

[0001] The invention belongs to the technical field of microorganisms, and particularly relates to a Lactobacillus plantarum TY-P23 and an application thereof. Background Art

[0002] At present, with the change of modern lifestyle, the aggravation of environmental pollution, unbalanced diet, lack of exercise, lack of sleep and other factors, the human immune regulation function may be unbalanced, thus causing many health problems such as infection, chronic inflammation, allergic reaction and autoimmune disease. Therefore, how to maintain the balance and health of the immune system has become a highly concerned issue in the field of public health.

[0003] In recent years, studies have shown that some strains play a certain role in regulating the immune system. These strains can enhance intestinal barrier function, increase the number and function of immune cells, promote the production of immunomodulatory factors, and other ways to regulate immune activity.

[0004] At present, the strains reported to have immunomodulatory functions have unsatisfactory effects. At the same time, it is found that the strains' immunomodulatory activity is strain-specific. Therefore, there is an urgent need to screen strains that have better effects on regulating the body's immune activity. Summary of the invention

[0005] The present invention separates a strain of bacteria from human milk, which is identified as Lactobacillus plantarum and can significantly improve the body's immune ability and improve the body's intestinal damage.

[0006] In order to achieve the above object, the present invention can adopt the following technical solutions:

[0007] The present invention provides a Lactobacillus plantarum TY-P23, whose deposit number is CGMCC No: 30876.

[0008] Another aspect of the present invention provides a composition comprising the Lactobacillus plantarum TY-P23 of the present invention.

[0009] Preferably, the above composition may include a fermentation product or a culture.

[0010] In another aspect, the present invention provides a preparation comprising the composition of the present invention.

[0011] Preferably, the above-mentioned preparation can be an inactivated bacterium agent or a microecological bacterium agent.

[0012] Preferably, the above-mentioned preparation includes food, medicine or health care product.

[0013] In another aspect, the present invention provides a use of the Lactobacillus plantarum TY-P23 or the composition of the present invention in the preparation of a preparation for improving the immune ability of an organism and / or improving intestinal damage of an organism.

[0014] Preferably, the above application includes: application of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for improving the reduced immunity and / or intestinal damage caused by cyclophosphamide.

[0015] Preferably, the above application includes one or more combinations of the following applications:

[0016] (a) Use of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for improving an immune organ index of a body;

[0017] (b) Use of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for increasing the number of immune cells in a body;

[0018] (c) Use of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for improving pathological damage to intestinal tissues of a body;

[0019] (d) Use of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for promoting the expression of intestinal immune-related cytokines;

[0020] (e) Use of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for promoting the expression of tight junction protein Claudin-1.

[0021] Preferably, in the above application,

[0022] Application (a) includes: application of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for alleviating atrophy of spleen and thymus immune organs;

[0023] In application (b), the body's immune cells include one or more of leukocytes, neutrophils, monocytes, eosinophils or basophils;

[0024] In application (d), the relevant cytokines include one or more of IL-2, IL-10, IL-1β or INF-γ.

[0025] The preservation information of Lactobacillus plantarum TY-P23 in the present invention is as follows: preservation institution: General Microbiology Center of China Microorganism Culture Collection Administration (CGMCC); address: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing; preservation date: June 7, 2024; preservation number: CGMCC No.30876; classification name: Lactobacillus plantarum.

[0026] The beneficial effects of the present invention include at least:

[0027] (1) The Lactobacillus plantarum TY-P23 provided by the present invention can improve the immune organ index of immunosuppressed mice and inhibit spleen and thymus atrophy caused by cyclophosphamide.

[0028] (2) The Lactobacillus plantarum TY-P23 provided by the present invention can increase the number of immune cells in immunosuppressed mice and improve the body's systemic immune function.

[0029] (3) The Lactobacillus plantarum TY-P23 provided by the present invention can improve pathological damage to mouse colon tissue.

[0030] (4) The Lactobacillus plantarum TY-P23 provided by the present invention can enhance the intestinal immune function by promoting the mRNA expression of inflammatory factors.

[0031] (5) The Lactobacillus plantarum TY-P23 provided by the present invention repairs and enhances the intestinal mucosal barrier function by enhancing the expression of tight junction proteins. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 This is the colony morphology of Lactobacillus plantarum TY-P23;

[0033] Figure 2 This is the fermentation broth of Lactobacillus plantarum TY-P23;

[0034] Figure 3 The effect of Lactobacillus plantarum TY-P23 on the spleen index of mice;

[0035] Figure 4 The effect of Lactobacillus plantarum TY-P23 on the thymus index of mice;

[0036] Figure 5 The effect of Lactobacillus plantarum TY-P23 on the number of peripheral blood leukocytes in mice;

[0037] Figure 6 The effect of Lactobacillus plantarum TY-P23 on the number of neutrophils in peripheral blood of mice;

[0038] Figure 7 The effect of Lactobacillus plantarum TY-P23 on the number of peripheral blood lymphocytes in mice;

[0039] Figure 8 The effect of Lactobacillus plantarum TY-P23 on the number of peripheral blood mononuclear cells in mice;

[0040] Fig. 9 The effect of Lactobacillus plantarum TY-P23 on the number of eosinophils in the peripheral blood of mice;

[0041] Fig.10 The effect of Lactobacillus plantarum TY-P23 on the number of peripheral blood basophils in mice;

[0042] Fig.11 Shown is the effect of Lactobacillus plantarum TY-P23 on the morphology of mouse colon tissue;

[0043] Fig.12 The effect of Lactobacillus plantarum TY-P23 on the expression level of IL-2 in the intestinal tissue of mice;

[0044] Fig.13 The effect of Lactobacillus plantarum TY-P23 on the expression level of IL-10 in the intestinal tissue of mice;

[0045] Fig.14 The effect of Lactobacillus plantarum TY-P23 on the expression level of IL-1β in the intestinal tissue of mice;

[0046] Fig.15 The effect of Lactobacillus plantarum TY-P23 on the expression level of INF-γ in the intestinal tissue of mice;

[0047] Fig.16 The effect of Lactobacillus plantarum TY-P23 on the expression level of tight junction protein Claulin-1 in the intestinal tissue of immunocompromised mice;

[0048] Figures 2 to 16 In the table, *** indicates P < 0.001, ** indicates P < 0.01, and * indicates P < 0.05, all of which indicate significant differences compared with the cyclophosphamide model group; data are presented as Mean ± SEM. DETAILED DESCRIPTION

[0049] The examples are provided to better illustrate the present invention, but the present invention is not limited to the examples. Therefore, those skilled in the art may make non-essential improvements and adjustments to the implementation scheme according to the above invention content, which still fall within the protection scope of the present invention.

[0050] The terms used herein are only used to describe specific embodiments and are not intended to limit the present disclosure. Unless the context has a significantly different meaning, expressions in the singular include expressions in the plural. As used herein, it should be understood that terms such as "include", "have", "include" are intended to indicate the presence of features, numbers, operations, components, parts, elements, materials or combinations. The terms of the present invention are disclosed in the specification, and are not intended to exclude the possibility that one or more other features, numbers, operations, components, parts, elements, materials or combinations thereof may exist or may be added. As used herein, " / " may be interpreted as "and" or "or", depending on the circumstances.

[0051] In the present invention, "enhancing the body's immune ability" refers to restoring the body to a healthy immune state, and does not mean additionally improving the immune ability on top of a healthy state.

[0052] The Latin name of "Lactobacillus plantarum" in the present invention is the old Latin name of Lactobacillus plantarum, and its new Latin name is "Lactiplantibacillus plantarum".

[0053] The embodiment of the present invention provides a Lactobacillus plantarum TY-P23, whose preservation number is CGMCC No: 30876.

[0054] It should be noted that the Lactobacillus plantarum TY-P23 in the present invention is isolated from human milk and has no side effects; the 16sRNA sequence of the Lactobacillus plantarum TY-P23 is found to contain the sequence shown in SEQ ID NO: 1 through sequencing.

[0055] The embodiment of the present invention also provides a composition comprising the Lactobacillus plantarum TY-P23 of the present invention.

[0056] It should be noted that, in order to improve the application effect of Lactobacillus plantarum TY-P23, Lactobacillus plantarum TY-P23 can be used in the form of a composition.

[0057] In some specific examples, the composition can be a fermentation product or a culture.

[0058] It should be noted that the above-mentioned composition can be in the form of a fermentation product or culture containing Lactobacillus plantarum TY-P23, wherein the fermentation product refers to various substances produced by the fermentation process using Lactobacillus plantarum TY-P23 under suitable culture conditions; the culture refers to the strain; the culture refers to the microbial community obtained by cultivation and reproduction under artificially specified conditions.

[0059] An embodiment of the present invention also provides a preparation comprising the composition of the present invention.

[0060] It should be noted that the plant lactobacillus TY-P23 in the present invention can be prepared into a stable preparation for use, and the preparation form is a form known in the art, such as powder, tablet, liquid dosage form, granule or capsule dosage form, etc. There are differences in the auxiliary materials added to different dosage forms, which can be added according to what is known in the art.

[0061] In some specific examples, the above-mentioned preparation can be an inactivated bacterial agent or a microecological bacterial agent.

[0062] It should be noted that the above-mentioned preparations can be preparations prepared from inactivated bacteria agents, or can be microecological preparations prepared from live bacteria. The specific dosage form can be selected according to specific needs, and the preparation method can be selected by those known in the art.

[0063] In some specific examples, the preparation includes food, medicine or health care product.

[0064] It should be noted that, in terms of the application scope of the preparation, the above-mentioned preparation can be prepared into functional foods without therapeutic effects, such as probiotic beverages, dairy beverages (such as yogurt), and can also be prepared into probiotic biscuits, probiotic powder and other foods; of course, it can also be prepared into medicines with therapeutic effects with pharmaceutical excipients; similarly, it can be prepared into health products with certain health functions, which can be prepared specifically according to the effects to be achieved.

[0065] The embodiment of the present invention also provides a use of the Lactobacillus plantarum TY-P23 of the present invention or the composition of the present invention in the preparation of a preparation for improving the immune ability of an organism and / or improving intestinal damage of an organism.

[0066] It should be noted that the plant lactobacillus TY-P23 in the present invention or the composition in the present invention can be used in the preparation of a preparation, and the preparation can be a food, a medicine or a health product; it should be understood that the plant lactobacillus TY-P23 in the present invention, as a probiotic, has the properties of a functional food, a therapeutic drug and a health product. When it plays a functional role as a food, the above-mentioned preparation is a food, when it plays a therapeutic role, the above-mentioned preparation is a medicine, and when it plays a health care role, the above-mentioned preparation is a health product.

[0067] It should also be noted that, as mentioned above, the above-mentioned preparations can be powders, tablets, liquid dosage forms, granules or capsule dosage forms, etc., and the excipients added to different dosage forms are different and can be added according to what is known in the art.

[0068] In some specific examples, the above application includes: application of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for improving the reduced immunity and / or intestinal damage caused by cyclophosphamide.

[0069] It should be noted that, as described above, the plant lactobacillus TY-P23 or composition of the present invention can improve the body's immune ability and / or improve the body's intestinal damage, and is mainly suitable for reduced immunity and / or intestinal damage caused by cyclophosphamide; when used in reduced immunity and / or intestinal damage caused by cyclophosphamide, it can significantly improve immune ability and improve intestinal damage.

[0070] In some specific examples, the above application includes one or more combinations of the following applications:

[0071] (a) Use of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for improving an immune organ index of a body;

[0072] (b) Use of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for increasing the number of immune cells in a body;

[0073] (c) Use of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for improving pathological damage to intestinal tissues of a body;

[0074] (d) Use of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for promoting the expression of intestinal immune-related cytokines;

[0075] (e) Use of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for promoting the expression of tight junction protein Claudin-1.

[0076] It should be noted that the plant lactobacillus TY-P23 or the composition in the present invention can improve the body's immune organ index, increase the number of immune cells, improve the body's intestinal tissue pathological damage, promote the expression of intestinal immune-related cytokines, and promote the expression of tight junction protein Claudin-1, thereby achieving the purpose of improving the body's reduced immunity and / or intestinal damage caused by cyclophosphamide.

[0077] In some specific examples, in the above applications,

[0078] Application (a) includes: application of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for alleviating spleen and thymus immune organ atrophy; specifically, the above-mentioned improvement of the body's immune organ index mainly includes the preparation for alleviating spleen and thymus immune organ atrophy;

[0079] In application (b), the body's immune cells include one or more of leukocytes, neutrophils, monocytes, eosinophils or basophils; specifically, Lactobacillus plantarum TY-P23 can especially increase the number of immune cells in peripheral blood, especially one or more of leukocytes, neutrophils, monocytes, eosinophils or basophils;

[0080] In application (c), the relevant cytokines include one or more of IL-2, IL-10, IL-1β or INF-γ.

[0081] It should also be noted that in the Lactobacillus plantarum TY-P23 or the composition of the present invention, the number of viable bacteria of Lactobacillus plantarum TY-P23 is preferably ≥ 1×10 8 CFU / g or 1×10 8 CFU / mL.

[0082] In order to better understand the present invention, the content of the present invention is further explained below in conjunction with specific examples, but the content of the present invention is not limited to the following examples.

[0083] 1. Screening and identification of Lactobacillus plantarum TY-P23

[0084] (I) Screening

[0085] The sample was derived from human milk. After pretreatment, it was stored in a -80°C refrigerator in 20% glycerol. After being taken out and thawed, 1 mL of the sample was mixed and added to 9 mL. It was gradient diluted with 0.9% saline. The appropriate gradient dilution was selected and spread on MRS solid culture medium. It was cultured at 37°C for 48 hours. The colonies were picked and streaked on MRS solid culture medium for purification. Single colonies were picked and transferred to MRS liquid culture medium for bacterial enrichment and preserved in 30% glycerol to obtain strain TY-P23.

[0086] (II) Identification

[0087] The 16SrDNA of TY-P23 was amplified and sequenced, and the 16SrDNA sequence contained the sequence shown in SEQ ID NO.1. The sequence was compared with the nucleic acid sequence in NCBI, and the result showed that the strain was Lactobacillus plantarum, and was named Lactobacillus plantarum TY-P23.

[0088] In addition, the colony picture of this strain after culturing in MRS medium at 37°C for 18 hours is as follows Figure 1 As shown, the fermentation broth after fermentation of the strain is as follows Figure 2 shown.

[0089] 2. Animal Experiments

[0090] (I) Preparation of Lactobacillus plantarum TY-P23 bacterial suspension

[0091] Lactobacillus plantarum TY-P23 was inoculated into MRS solid medium and cultured at 37°C for 48 hours, and its colonies were observed and its bacterial bodies were observed under a microscope. Then, it was inoculated into MRS liquid medium and cultured at 37°C for 18 hours, and then transferred into fresh MRS liquid medium and cultured under the same conditions for 18 hours. The fermentation liquid was centrifuged at 6000g for 15 minutes, and the bacterial bodies were washed with 0.9% saline and centrifuged again at 6000g for 10 minutes to obtain bacterial bodies, which were resuspended with 30% sucrose solution and frozen at -80°C for use. Before gavage, the bacterial bodies were resuspended with sterile saline and the number of viable bacteria was adjusted to 5×10 8 CFU / cell, and made into bacterial suspension.

[0092] (II) Animals and breeding

[0093] The experimental animals were female SPF-grade BALB / c mice (6 weeks old, weighing 19 g-20 g), purchased from Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd.; the mice were housed in the Experimental Animal Center of Jiangnan University (temperature 21°C-25°C, relative humidity 50%-60%, 12 h day and night cycle) and had free access to water.

[0094] (III) Experimental process

[0095] After 7 days of adaptive feeding according to the above method, the experimental mice were randomly divided into a blank control group (blank group), a cyclophosphamide model group (model group), a levamisole hydrochloride Yangshen group (Yangshen group, 40 mg / kg / d, based on body weight, levamisole hydrochloride Yangshen is a commonly used therapeutic drug) and a plant lactobacillus TY-P23 group (TY-P23 group), with 6 mice in each group; the normal group and the model group were gavaged with sterile saline, the Yangshen group was gavaged with levamisole hydrochloride, and the TY-P23 group was gavaged with plant lactobacillus TY-P23, once a day for 28 consecutive days. On the 22nd and 23rd days, the blank group mice were intraperitoneally injected with saline, and the other groups were intraperitoneally injected with cyclophosphamide 80 mg / kg / d. After the experiment, the mice were killed by dislocation after blood was taken from the eyeballs, and the thymus and spleen were weighed to calculate the spleen index and thymus index; the colon tissue was taken for subsequent HE staining and determination of immune regulation-related inflammatory factors.

[0096] (IV) Effect of Lactobacillus plantarum TY-P23 on alleviating cyclophosphamide-induced immunosuppression in mice

[0097] (1) Mouse immune organ index

[0098] After the mice were killed, the thymus and spleen were carefully removed, rinsed with PBS buffer, and dried with filter paper; then the thymus and spleen were weighed and recorded, and the ratio of thymus or spleen mass (mg) to body mass (g) was calculated.

[0099] The results are as follows Figure 3 and Figure 4 As shown in the figure, compared with the blank group, the spleen index and thymus index of the model group mice were significantly reduced (P<0.001). Compared with the model group, the thymus index of the Yangshen group mice increased significantly, and the spleen index (P<0.05) and thymus index (P<0.01) of the Lactobacillus plantarum TY-P23 group mice increased to varying degrees, and were better than the Yangshen group; the above results show that Lactobacillus plantarum TY-P23 improves the immune organ index of immunocompromised mice.

[0100] (2) Changes in the number of peripheral blood immune cells in mice

[0101] Blood was collected from the eyeball and placed in an anticoagulant blood collection tube containing EDTA anticoagulant, and then the white blood cells in the whole blood of the mice were counted using a fully automatic blood cell analyzer.

[0102] The results are as follows Figure 5 , Figure 6 , Figure 7 , Figure 8 , Fig. 9 and Fig.10 As shown in the results, compared with the blank group, the number of peripheral blood leukocytes, lymphocytes, neutrophils, monocytes, eosinophils and basophils in the cyclophosphamide model group mice was significantly reduced (P<0.01); compared with the model group, oral administration of Lactobacillus plantarum TY-P23 could significantly increase the number of leukocytes, neutrophils, monocytes, eosinophils and basophils, among which the effect on basophils was the same as that in the model group, and the effect on leukocytes, neutrophils, monocytes and eosinophils was significantly better than that in the model group; the above results showed that Lactobacillus plantarum TY-P23 could improve the body's immune ability.

[0103] (V) Effect of Lactobacillus plantarum TY-P23 on alleviating cyclophosphamide-induced intestinal damage in mice

[0104] (1) HE staining to detect pathological damage of colon tissue

[0105] After the mice in each group were killed, 1 cm of proximal colon tissue was obtained, fixed with 4% paraformaldehyde for 24 h, embedded in paraffin and cut into 5 μm slices; the tissue slices were dewaxed with xylene and then stained with hematoxylin and eosin for observation.

[0106] The results are as follows Fig.11As shown in the results, the intestinal villi of the colon tissue of the mice in the blank group were arranged tightly, well and neatly, with complete colon mucosa, crypts and folds; the colon mucosa of the mice in the model group was severely damaged, with incomplete structure and loose arrangement, accompanied by villus shedding, crypt damage and inflammatory cell infiltration; the pathological damage of the colon tissue of the mice in the Yangshen group and the Lactobacillus plantarum TY-P23 group was improved, indicating that Lactobacillus plantarum TY-P23 has the effect of alleviating colon tissue lesions and damage.

[0107] (2) Expression levels of immune inflammatory factors in colon tissue

[0108] The total RNA of colon tissue was extracted by Trizol method. 100 mg of mouse colon tissue was added with 1 mL of Trizol reagent and ground in a tissue homogenizer. Then, the mixture was centrifuged at 4°C and 3000 rpm / min for 10 min and the supernatant was aspirated. RNA was converted into cDNA using StarScript reverse transcription kit. The gene expression level was detected by real-time quantitative PCR. PCR system: 7.6 μL ddH2O, 10 μL Mix (2×SYBR Green qPCR Mix), 0.4 μL ROX (50×ROX ReferenceDye), 0.5 μL upstream primer, 0.5 μL downstream primer (primer sequence see Table 1 below), 1 μL cDNA template. The housekeeping gene β-actin was used as the internal reference. The relative expression of mRNA was calculated by relative quantification method. The expression of all inflammatory factor genes to be detected was expressed by Ct value and expressed by 2 -ΔΔCt To calculate the relative mRNA expression levels of inflammatory factors in the model group and Lactobacillus plantarum TY-P23 group.

[0109] Table 1 Primer sequence information

[0110]

[0111] The expression of IL-2, IL-10, IL-1β and INF-γ mRNA was as follows Fig.12 , Fig.13 , Fig.14 and Fig.15 As shown in the figure, compared with the blank group, the relative mRNA expression levels of immune factors IL-2, IL-10, IL-1β and INF-γ in the colon tissue of the model group were significantly decreased (P<0.05), indicating that cyclophosphamide treatment significantly reduced the intestinal immune function; compared with the model group, Lactobacillus plantarum TY-P23 treatment significantly increased the relative expression levels of IL-2, IL-10, IL-1β and INF-γ in the colon tissue, indicating that Lactobacillus plantarum TY-P23 promoted the expression of immune factors and thus improved the function of intestinal immunity.

[0112] (3) Expression level of tight junction protein Claudin-1 in colon tissue

[0113] According to the method described in (2) above, the expression level of tight junction protein Claudin-1 was detected by fluorescence quantitative analysis. The primer sequences of Claudin-1 were: Forward 5'-GGGGACAACATCGTGACCG-3', Reverse 5'-AGGAGTCGAAGACTTTGCACT-3'.

[0114] The results are as follows Fig.16 As shown in the results, compared with the blank control group, the relative mRNA expression of the immune factor Claudin-1 in the colon tissue of the model group was significantly decreased (P<0.05), and the expression level of Lactobacillus plantarum TY-P23 was significantly higher than that of the model group and better than that of the Yangshen group, indicating that Lactobacillus plantarum TY-P23 can improve the intestinal barrier function by enhancing the expression of tight junction proteins.

[0115] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be covered by the scope of the claims of the present invention.

Claims

1. A Lactobacillus plantarum TY-P23, whose deposit number is CGMCC No: 30876.

2. A composition comprising the Lactobacillus plantarum TY-P23 according to claim 1.

3. The composition according to claim 2, characterized in that The composition includes a fermentation or culture.

4. A preparation comprising the composition of claim 2 or 3.

5. The preparation according to claim 4, characterized in that The preparation is an inactivated bacteria agent or a microecological bacteria agent.

6. The preparation according to claim 4 or 5, characterized in that Preparations include food, medicine or health products.

7. Use of the Lactobacillus plantarum TY-P23 according to claim 1 or the composition according to claim 2 or 3 in the preparation of a preparation for improving the immune ability of an organism and / or improving intestinal damage of an organism.

8. The use according to claim 7, characterized in that: The application includes: application of Lactobacillus plantarum TY-P23 or the combination in preparing a preparation for improving the reduced immunity and / or intestinal damage caused by cyclophosphamide.

9. The use according to claim 7 or 8, characterized in that: Applications include one or a combination of the following: (a) Use of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for improving an immune organ index of a body; (b) Use of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for increasing the number of immune cells in a body; (c) Use of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for improving pathological damage to intestinal tissues of a body; (d) Use of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for promoting the expression of intestinal immune-related cytokines; (e) Use of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for promoting the expression of tight junction protein Claudin-1.

10. The use according to claim 9, characterized in that: in, Application (a) includes: application of Lactobacillus plantarum TY-P23 or the composition in the preparation of a preparation for alleviating atrophy of spleen and thymus immune organs; In application (b), the body's immune cells include one or more of leukocytes, neutrophils, monocytes, eosinophils or basophils; In application (d), the relevant cytokines include one or more of IL-2, IL-10, IL-1β or INF-γ.

Images